← Home
Sonoco Products 
Industry & manufacturing / Packaging Solutions and Services
Press Releases
| Date | Press release |
|---|---|
| 2025-04-29 16:30:00 | Sonoco Reports First Quarter 2025 Results Hartsville, s.c., april 29, 2025 (globe newswire) -- sonoco products company (“sonoco” or the “company”) (nyse: son), a core mid-cap growth and value equity which is a global leader in high-value sustainable packaging, today reported financial results for the first quarter ended march 30, 2025. |
| 2025-04-28 14:52:00 | Sonoco To Report First Quarter 2025 Results Hartsvlle, s.c., april 28, 2025 (globe newswire) -- sonoco products company (“sonoco” or the “company”) (nyse: son), a global leader in high-value sustainable packaging, will announce first quarter 2025 results on tuesday, april 29, 2025 after the market closes. the company will host a conference call to discuss these results on wednesday, april 30, 2025, at 8:30 a.m. eastern time. |
| 2025-04-22 20:00:00 | Sonoco Named To Usa Today America’s Climate Leaders 2025 List Hartsville, s.c., april 22, 2025 (globe newswire) -- sonoco products company (nyse: son), a global leader in high-value sustainable packaging, has been named to usa today’s list of america’s climate leaders 2025. |
| 2025-04-16 11:50:00 | Sonoco Increases Quarterly Common Stock Dividend Hartsville, s.c., april 16, 2025 (globe newswire) -- the board of directors of sonoco (nyse: son) today increased its quarterly common stock dividend to $0.53 per shares as it celebrated the 100th consecutive year of paying dividends to its shareholders at the company’s annual meeting. |
| 2025-04-04 09:00:00 | Sonnet’s Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-resistant Ovarian Cancer, Including A Partial Response At The Highest Dose Topline safety data in sb221 study suggest clinical benefit of son-1010 in combination with atezolizumab (tecentriq ® ) |
Explore more press releases! Sign up for free! or log in
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal